Q-omics provides the consensus-scored MALAT1 profile across patient tissues and cancer cell-line models. MALAT1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MALAT1 is differentially expressed in 7, with the highest sampling consensus in COAD. Additionally, MALAT1 RNA expression shows 19,494 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, COAD, and THYM as cancer lineages where MALAT1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MALAT1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MALAT1 survival associations across molecular data types. MALAT1 RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MALAT1 RNA expression–survival associations across cancer types. High MALAT1 expression shows unfavorable associations in KIRC and KICH, but favorable associations in STAD, ACC, HNSC and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify KIRC as the clearest survival context for MALAT1 RNA expression.
This table summarizes MALAT1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for MALAT1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MALAT1 shows lower tumor expression in BRCA and LUSC and higher tumor expression in COAD, LIHC, CHOL and KICH. The COAD box plot shows higher MALAT1 RNA expression in tumor versus normal tissue (log2 FC = +1.557, t-test p < 0.001).
This table shows molecular features associated with MALAT1 in patient tissues and cancer cell lines. In patient samples, MALAT1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, MALAT1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY.
